Estrogen Receptor Antibody [NR3Ga-1] | 33-909

Estrogen Receptor Antibody [NR3Ga-1] | 33-909 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Estrogen Receptor alpha protein (aa 2-185) was used as the immunogen for this antibody.

Research Area: Signal Transduction

Tested Application: WB, IHC

Application: WB: use antibody at 0.5-1 ug/ml
IHC (FFPE) : 1-2 ug/ml for 30 minutes at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Titration of the antibody may be required for optimal performance.

1. Staining of FFPE tissues requires boiling sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: NR3Ga-1

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: ESR1 Antibody: ER, ESR, Era, ESRA, ESTRR, NR3A1, Estrogen receptor, ER-alpha, ER

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Estrogen receptor (ER) is an important regulator of growth and differentiation in the mammary gland. It is found in two forms, alpha and beta. Both forms are widely expressed, however, alpha is the predominant form in endometrium and breast cancer cells, and beta is more highly expressed in brain, kidney, heart, lung and bone. Activated Estrogen receptor dimerizes and forms both homo- and heterodimers. ER contains five domains: A-F. The A and B domain are able to weakly activate ER in the absence of ligand. The C domain binds DNA and the E domain contains the ligand binding site. Presence of ER in breast tumors indicates an increased likelihood of response to anti-estrogen (e.g. tamoxifen) therapy. This antibody is specific to estrogen receptor alpha and shows minimal cross-reaction with other members of the family.